FGFR Inhibitor Stymies Gastric Cancer.
Sign Up to like & getrecommendations! Published in 2021 at "Cancer discovery"
DOI: 10.1158/2159-8290.cd-nb2021-0312
Abstract: In the phase II FIGHT trial, adding bemarituzumab to chemotherapy led to longer progression-free survival and overall survival in patients with advanced FGFR2b-positive gastric or gastroesophageal junction cancers. However, the agent was also associated with… read more here.
Keywords: inhibitor stymies; fgfr inhibitor; cancer; gastric cancer ... See more keywords